Announced details
Treatment and prevention of infections caused by SARS-CoV-2, including post-exposure prophylaxis against COVID-19.
Created through joint research with Hokkaido University. Manufactured and marketed by Shionogi & Co.,Ltd.
Xocova Tablets 125 mg: ¥7,090 per tablet
The impact on consolidated results for the fiscal year ending March 2026 will be minor.
The company does not address Contract Value.
SCORPIO-PEP study, CROI 2025, JAMA Network Open, the Vaccine Committee and COVID-19 Vaccine Task Force of the Japanese Association for Infectious Diseases, and others
| Item | Details |
|---|---|
| Names of Products / Services Covered | Xocova Tablets 125 mg (generic name: ensitrelvir fumaric acid) |
| Relationship with the Company | Created through joint research with Hokkaido University. Manufactured and marketed by Shionogi & Co.,Ltd. |
| Offering price | Xocova Tablets 125 mg: ¥7,090 per tablet |
| Applicable area | Treatment and prevention of infections caused by SARS-CoV-2, including post-exposure prophylaxis against COVID-19. |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2026 will be minor. |
| Source | SCORPIO-PEP study, CROI 2025, JAMA Network Open, the Vaccine Committee and COVID-19 Vaccine Task Force of the Japanese Association for Infectious Diseases, and others |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Approval was obtained based on favorable results from the global Phase 3 post-exposure prophylaxis study (SCORPIO-PEP).